secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001104659-24-108360
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA Clears Annovis to Start Pivotal Phase 3 Alzheimer's Studies for Buntanetap
------------------------------------------------------------------------------

- FDA clearance to proceed with pivotal Phase 3 studies for buntanetap in early Alzheimer's disease.
- Two trials: a 6-month symptomatic study and an 18-month disease-modifying study.
- A well-executed 6-month trial may support NDA filing within one year of initiation.
- No safety concerns raised; FDA confirmed liver enzymes, drug interactions, dose selection acceptable.
- CEO Maria Maccecchini says trial initiation planned early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924108360/0001104659-24-108360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924108360/tm2426152d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-108360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer